December 20, 2019
As we approach 2020, we see enormous possibilities to advance toward our collective goal to end the HIV epidemic–and we see even more enormous opportunities for our work together!
Several new interventions face critical moments in 2020: from an anticipated regulatory opinion on the dapivirine ring to trial results on the first AMP studies; from the development of a novel trial design to study oral F/TAF as PrEP in women to advances toward a possible dual pill for HIV prevention and contraception; from setting new global targets for prevention to evaluations of innovative prevention delivery under PEPFAR’s DREAMS program; from understanding the results of the recent “universal test and treat” trial results to acting on their implications and expanding the concept to testing that connects to both treatment and prevention.
2020 will have much to teach us. The year will offer unique opportunities to move HIV prevention forward, and we must not squander them. The challenge of stalled or rising rates of new infections remains formidable, with new infections around 1.7 million annually, a far cry from the 2020 target of fewer than 500,000. AVAC looks squarely at this challenge with cross-cutting analysis and an advocacy agenda to match in our 2019 annual report, Now What?. In 2020, we hope you’ll join us in helping to answer the question and achieve an ambitious set of commitments.
In addition, 2020 marks AVAC’s 25th year of action! Without your long-standing support, we could not have reached this milestone, and we hope you’ll help us reflect, celebrate and recommit to our work bringing together the voices and ideas that push HIV prevention center stage in the fight against HIV.
Please consider a contribution by visiting www.avac.org/donate. You can also shop online at Amazon via smile.amazon.com and select “AVAC” and a portion of your purchase is donated to us—at no additional cost to you.
Many thanks for your partnership and for your continued support, and warmest wishes for the New Year!